EDIT
Price
$2.62
Change
+$0.10 (+3.97%)
Updated
Oct 2 closing price
Capitalization
385.49M
37 days until earnings call
Intraday BUY SELL Signals
NVAX
Price
$10.46
Change
-$0.14 (-1.32%)
Updated
Oct 2 closing price
Capitalization
1.78B
33 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs NVAX

EDIT vs NVAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. NVAX commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and NVAX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
EDIT vs NVAX: Fundamental Ratings
EDIT
NVAX
OUTLOOK RATING
1..100
6132
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8141
P/E GROWTH RATING
1..100
10013
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for NVAX (75). This means that EDIT’s stock grew somewhat faster than NVAX’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that EDIT’s stock grew similarly to NVAX’s over the last 12 months.

EDIT's SMR Rating (99) in the Biotechnology industry is in the same range as NVAX (100). This means that EDIT’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for EDIT (81). This means that NVAX’s stock grew somewhat faster than EDIT’s over the last 12 months.

NVAX's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that NVAX’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITNVAX
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (EDIT: $2.62 vs. NVAX: $10.46)
Brand notoriety: EDIT: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 79% vs. NVAX: 79%
Market capitalization -- EDIT: $385.49M vs. NVAX: $1.78B
EDIT [@Biotechnology] is valued at $385.49M. NVAX’s [@Biotechnology] market capitalization is $1.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green while NVAX’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, NVAX is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 6 bearish.
  • NVAX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а +1.55% price change this week, while NVAX (@Biotechnology) price change was -1.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

NVAX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
NVAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PSCM96.061.80
+1.91%
Invesco S&P SmallCap Materials ETF (PSCM)
BLOK61.820.46
+0.75%
Amplify Blockchain Technology ETF (BLOK)
SAT25.06N/A
N/A
Saratoga Investment Corp
CNBS26.13-0.14
-0.55%
Amplify Seymour Cannabis ETF (CNBS)
OIA5.60-0.14
-2.44%
INVESCO Municipal Income OPPORTUNITIES TRUST

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with BEAM. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+3.97%
BEAM - EDIT
66%
Loosely correlated
+0.45%
CRBU - EDIT
64%
Loosely correlated
N/A
CRSP - EDIT
63%
Loosely correlated
-0.02%
PRME - EDIT
63%
Loosely correlated
-0.33%
NTLA - EDIT
59%
Loosely correlated
+1.16%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.32%
CRSP - NVAX
47%
Loosely correlated
-0.02%
MRNA - NVAX
45%
Loosely correlated
+0.57%
BNTX - NVAX
43%
Loosely correlated
+0.05%
EDIT - NVAX
42%
Loosely correlated
+3.97%
RXRX - NVAX
41%
Loosely correlated
+1.23%
More